INDV
$29.30-1.20 (-3.93%)
Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Recent News
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why
AGIO sinks 23% as mixed phase III data for mitapivat in SCD and an FDA review delay for thalassemia dent investors' confidence in its key growth drug.
How Indivior’s Upsized $450 Million Convertible Notes and Buybacks May Impact Indivior (INDV) Investors
In March 2026, Indivior Pharmaceuticals, Inc. completed an upsized private offering of US$450,000,000 in 0.625% convertible senior unsecured notes due March 15, 2031, using the proceeds to repay existing credit facilities, repurchase about 2,400,000 shares, and fund general corporate purposes. Alongside this financing move, stronger-than-expected 2025 earnings and recent insider share purchases have highlighted improving operations and management confidence in the business. Next, we’ll...
Implied Volatility Surging for Indivior Pharmaceuticals Stock Options
Investors need to pay close attention to INDV stock based on the movements in the options market lately.
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Recent Name Change
What just happened with Indivior Pharmaceuticals Indivior Pharmaceuticals (INDV) has drawn fresh attention after recently changing its name from Indivior PLC to Indivior Pharmaceuticals, Inc., a shift that puts its US operations and buprenorphine based treatment portfolio in clearer focus for investors. See our latest analysis for Indivior Pharmaceuticals. While the recent name change has sharpened the focus on its prescription treatment portfolio, Indivior Pharmaceuticals’ 1-year total...